Czechia· CZ-0272052
EBGLYSS
A lebrikizumab product containing lebrikizumab, registered in Czechia by Almirall, S.A., Barcelona. The same ATC class is registered in 15 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Lebrikizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH10 (lebrikizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Lebrikizumab · ATC D11AH10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lebrikizumab costs, country by country.
Normalised to the WHO defined daily dose (8.9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lebrikizumab · price per daily dose (8.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.32
The record
At a glance
SÚKL (Czech Republic)- Active substance
- LEBRIKIZUMAB
- Manufacturer
- Almirall, S.A., Barcelona
- Country
- Czechia (CZ)
- ATC code
- D11AH10
- ATC class
- Lebrikizumab
- Defined daily dose
- 8.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02720521X2MLCZK 30126.25
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lebrikizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayEbglyssAlmirall, S.A.
- BelgiumEbglyss 250 mgAlmirall
- PolandEbglyssAlmirall, S.A.
- SwedenEbglyss 250 mg Injektionsvätska, lösning i förfylld injektionspennaAlmirall S.A.
- IcelandEbglyssAlmirall S.A.*
- SpainEBGLYSS 250 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAlmirall S.A.
- SwitzerlandEbglyss
- United StatesEBGLYSSEli Lilly and Company
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ebglyss
- Liechtenstein · Ebglyss
- Norway · Ebglyss
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fe9a8fb8-c07c-4e3c-905c-1bc7d104bd28 GET /v1/drugs/fe9a8fb8-c07c-4e3c-905c-1bc7d104bd28?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL PEP",
"source": "sukl",
"strength": "250MG",
"pack_size": "1X2ML",
"substance": "LEBRIKIZUMAB",
"cz_kod_sukl": "0272052",
"product_type": "BT",
"substance_codes": "18631",
"registration_state": "R",
"registration_number": "EU/1/23/1765/007"
}See everything about lebrikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.